Michael Henderson - Dec 4, 2025 Form 4 Insider Report for Apogee Therapeutics, Inc. (APGE)

Role: Chief Executive Officer, Director
Signature: /s/ Matthew Batters, as attorney-in-fact for Michael Henderson
Stock symbol: APGE
Transactions as of: Dec 4, 2025
Transactions value $: -$3,000,400
Form type: 4
Date filed: 12/5/2025, 08:00 PM
Previous filing: Nov 13, 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
HENDERSON MICHAEL THOMAS	Chief Executive Officer, Director	C/O APOGEE THERAPEUTICS, INC., 221 CRESCENT ST., BLDG. 17, STE. 102B, WALTHAM	/s/ Matthew Batters, as attorney-in-fact for Michael Henderson	2025-12-05	0001779990

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	APGE	Common Stock	Sale	-$3M	-40K	-3.14%	$75.01	1.23M	Dec 4, 2025	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id	Content
F1	This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025.
F2	The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $75.00 to $75.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Content

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025.

The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $75.00 to $75.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.